Sionna Therapeutics, Inc.

What they do

Sionna is advancing small molecules engineered to correct defects caused by the F508del mutation, the most common CFTR mutation, which occurs in the NBD1 domain and is carried by roughly 90% of people with CF. Its portfolio pairs NBD1 stabilizers with complementary CFTR modulators, either as a proprietary dual combination or as an add-on to the existing standard of care. Lead programs are SION-719 in a Phase 2a add-on trial and SION-451 in a Phase 1 dual-combination trial.

Revenue drivers

• SION-719 (NBD1 stabilizer, add-on to standard of care) — The lead program in the Phase 2a PreciSION CF trial testing SION-719 with Vertex's Trikafta; no product revenue is generated today and no approved product exists.
• SION-451 (NBD1 stabilizer, proprietary dual combinations) — In a Phase 1 trial in healthy volunteers in dual combinations with SION-2222 (galicaftor) and SION-109, the two complementary modulators; a future dual-combination franchise.
• Complementary CFTR modulators (SION-2222, SION-109, SION-3067) — Corrector and potentiator candidates intended to work synergistically with SION-451 in dual combinations; SION-2222 was previously studied by AbbVie in Phase 1 and Phase 2.
• No product revenue — The company has not generated any revenue from product sales or other sources and funds operations from equity proceeds.

Recent performance

Net loss was $75.3 million for 2025 versus $61.7 million for 2024, with an accumulated deficit of $256.4 million as of December 31, 2025. Second quarter 2026 net loss was $29.9 million versus $18.1 million in the second quarter of 2025, as R&D rose to $21.9 million from $15.4 million and G&A rose to $10.6 million from $6.5 million. Operating cash use was $66.3 million in 2025 versus $52.8 million in 2024. Cash, cash equivalents and marketable securities totaled $268.3 million as of June 30, 2026, sufficient per management to fund operations into 2028. The company reported no revenue.

Strategy

Sionna has prioritized development of a proprietary dual combination of an NBD1 stabilizer with one of its complementary modulators, while also pursuing SION-719 as an add-on to the standard of care. In April 2026 it completed enrollment in the Phase 2a PreciSION CF trial, and in August 2025 it initiated the Phase 1 dual-combination trial for SION-451. In March 2026 it entered an at-the-market sales agreement with Leerink for up to $250.0 million of common stock, under which no shares had been sold as of June 30, 2026. Cumulative net proceeds raised from preferred stock and its IPO were $530.0 million as of June 30, 2026.

Risks

• Clinical failure risk — Both lead programs depend on topline readouts from the Phase 2a PreciSION CF trial and the Phase 1 dual-combination trial, and any failure or delay would set the pipeline back materially.
• No revenue and continuing losses — Sionna has incurred operating losses every year since its 2019 inception, with a $256.4 million accumulated deficit at December 31, 2025, and may never achieve profitability.
• Additional capital needs — The company expects significant future losses and may need to raise additional capital, including through the new $250.0 million at-the-market facility, which could dilute existing stockholders.
• Dependence on the standard of care and larger competitors — SION-719's add-on strategy relies on combining with Vertex's Trikafta, and the company competes in a CF field dominated by approved CFTR modulators.

Outlook

Management says it remains focused on execution and delivering topline data from both the Phase 2a proof-of-concept trial and the Phase 1 dual-combination trial, which were guided for summer 2026. It expects the current cash position to fund operations into 2028. The company also presented encore Phase 1 and nonclinical data at the 49th European Cystic Fibrosis Conference in June 2026.